

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1612RXD

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page for STN Seminar Schedule - N. America
NEWS 2 JUL 02 LMEDLINE coverage updated
NEWS 3 JUL 02 SCISEARCH enhanced with complete author names
NEWS 4 JUL 02 CHEMCATS accession numbers revised
NEWS 5 JUL 02 CA/Capplus enhanced with utility model patents from China
NEWS 6 JUL 16 Capplus enhanced with French and German abstracts
NEWS 7 JUL 18 CA/Capplus patent coverage enhanced
NEWS 8 JUL 26 USPATFULL/USPAT2 enhanced with IPC reclassification
NEWS 9 JUL 30 USGENE now available on STN
NEWS 10 AUG 06 CAS REGISTRY enhanced with new experimental property tags
NEWS 11 AUG 06 BEILSTEIN updated with new compounds
NEWS 12 AUG 06 FSTA enhanced with new thesaurus edition
NEWS 13 AUG 13 CA/Capplus enhanced with additional kind codes for granted patents
NEWS 14 AUG 20 CA/Capplus enhanced with CAS indexing in pre-1907 records
NEWS 15 AUG 27 Full-text patent databases enhanced with predefined patent family display formats from INPADOCDB
NEWS 16 AUG 27 USPATOLD now available on STN
NEWS 17 AUG 28 CAS REGISTRY enhanced with additional experimental spectral property data
NEWS 18 SEP 07 STN AnaVist, Version 2.0, now available with Derwent World Patents Index
NEWS 19 SEP 13 FORIS renamed to SOFIS
NEWS 20 SEP 13 INPADOCDB enhanced with monthly SDI frequency
NEWS 21 SEP 17 CA/Capplus enhanced with printed CA page images from 1967-1998
NEWS 22 SEP 17 Capplus coverage extended to include traditional medicine patents
NEWS 23 SEP 24 EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS EXPRESS 19 SEPTEMBER 2007: CURRENT WINDOWS VERSION IS V8.2, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 19 SEPTEMBER 2007.
NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific

research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 17:32:42 ON 25 SEP 2007

=> file registry

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 17:32:54 ON 25 SEP 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 24 SEP 2007 HIGHEST RN 947820-54-4

DICTIONARY FILE UPDATES: 24 SEP 2007 HIGHEST RN 947820-54-4

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10524638.str

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=> s l1

SAMPLE SEARCH INITIATED 17:33:15 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 40 TO ITERATE

100.0% PROCESSED 40 ITERATIONS

5 ANSWERS

SEARCH TIME: 00.00.01

26/09/2007

Page 3

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 421 TO 1179
PROJECTED ANSWERS: 5 TO 234

L2 5 SEA SSS SAM L1

=> s l1 ful

FULL SEARCH INITIATED 17:33:19 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 742 TO ITERATE

100.0% PROCESSED 742 ITERATIONS 61 ANSWERS
SEARCH TIME: 00.00.01

L3 61 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	172.10	172.31

FILE 'CAPLUS' ENTERED AT 17:33:22 ON 25 SEP 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 25 Sep 2007 VOL 147 ISS 14
FILE LAST UPDATED: 24 Sep 2007 (20070924/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>


=> s l3

L4 2 L3

=> d abs bib hitstr 1-2

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN
GI

10459457



AB Title compds. [I; R1 = alkyl; R2, R3 = OH, alkoxy, cycloalkoxy, cycloalkylmethoxy, (fluoro)alkoxy; R2R3 = alkylendioxy; R4 = H, halo, NO2, alkyl, CF3, alkoxy; R5 = NR6C(:NR7)NR8R9, N:C(NR10R11)NR13R12, etc.; R6-R9 = H, alkyl, cycloalkyl, cycloalkylmethyl, cyano, hydroxyalkyl, alkoxyalkyl, etc.; R8R9N = (substituted) piperazinyl, azocanyl, azonanyl, azecanyl, tetrahydroisoquinolinyl, etc.; R10, R11 = H, alkyl, cycloalkyl, cycloalkylmethyl, hydroxyalkyl, alkoxyalkyl, etc.; R10R11N = 2,6-dimethylmorpholin-4-yl, 2,6-dimethylpiperidin-1-yl, 1H-1,2,4-triazol-1-yl, etc.; R12R13N = (substituted) piperazin-1-yl, azocan-1-yl, azonan-1-yl, azecan-1-yl, tetrahydroisoquinolin-2-yl, 3,5-dimethylpyrazol-1-yl, 4-benzylpiperidin-1-yl, 1H-1,2,4-triazol-1-yl, etc.], were prepared Thus, 1-[1-[4-(4aR,10bS)-9-ethoxy-8-methoxy-2-methyl-1,2,3,4,4a,10b-hexahydrobenzo[c][1,6]naphthyridin-6-ylphenyl]methanoyl]-2-methylisothiurea (preparation given), hexamethyleneimine, and Et3N were stirred at 80° for 4 days to give N-(1-aminoazocan-1-ylmethylene)-4-[(4aR,10bS)-9-ethoxy-8-methoxy-2-methyl-1,2,3,4,4a,10b-hexahydrobenzo[c][1,6]naphthyridin-6-yl]benzamide. I inhibited PDE3 with -log IC50 = 6.3-8.3.

AN 2004:182877 CAPLUS

DN 140:235693

TI Preparation of benzonaphthyridines as phosphodiesterase PDE4 or PDE3/4 inhibitors.

IN Kautz, Ulrich; Schmidt, Beate; Weinbrenner, Steffen; Hatzelmann, Armin; Barsig, Johannes; Marx, Degenhard; Kley, Hans-Peter; David, Michael; Rocker, Dirk; Flockerzi, Dieter

PA Altana Pharma A.-G., Germany

SO PCT Int. Appl., 65 pp.

CODEN: PIXXD2

DT Patent


LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004018465	A2	20040304	WO 2003-EP8996	20030813
	WO 2004018465	A3	20040527		
	WO 2004018465	A9	20050915		
	W: AE, AL, AU, BA, BR, CA, CN, CO, DZ, EC, GE, HR, ID, IL, IN, IS, JP, KR, LT, LV, MA, MK, MX, NO, NZ, PH, PL, SG, TN, UA, US, VN, YU, ZA, ZW				
	RW: AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR				
	CA 2495603	A1	20040304	CA 2003-2495603	20030813
	AU 2003263216	A1	20040311	AU 2003-263216	20030813


EP 1581533 A2 20051005 EP 2003-792314 20030813
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
 JP 2005537313 T 20051208 JP 2004-530142 20030813
 PRAI EP 2002-18529 A 20020817
 WO 2003-EP8996 W 20030813
 OS MARPAT 140:235693
 IT 667464-15-5P 667464-16-6P 667464-17-7P
 667464-18-8P 667464-19-9P 667464-20-2P
 667464-21-3P 667464-22-4P 667464-24-6P
 667464-25-7P 667464-26-8P 667464-27-9P
 667464-28-0P 667464-29-1P 667464-30-4P
 667464-31-5P 667464-32-6P 667464-33-7P
 667464-34-8P 667464-35-9P 667464-36-0P
 667464-37-1P 667464-38-2P 667464-39-3P
 667464-40-6P 667464-41-7P 667464-42-8P
 667464-43-9P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)
 (claimed compound; preparation of benzonaphthyridines as phosphodiesterase
 PDE4 or PDE3/4 inhibitors)
 RN 667464-15-5 CAPLUS
 CN Benzamide, N-(4,5-dihydro-1-methyl-4-oxo-1H-imidazol-2-yl)-4-[(4aR,10bS)-9-
 ethoxy-1,2,3,4,4a,10b-hexahydro-8-methoxy-2-methylbenzo[c][1,6]naphthyridi
 n-6-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 667464-16-6 CAPLUS
 CN Benzamide, 4-[(4aR,10bS)-9-ethoxy-1,2,3,4,4a,10b-hexahydro-8-methoxy-2-
 methylbenzo[c][1,6]naphthyridin-6-yl]-N-[(hexahydro-1(2H)-
 azocinyl)iminomethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 667464-17-7 CAPLUS

CN Benzamide, N-[(4-acetyl-1-piperazinyl)iminomethyl]-4-[(4aR,10bS)-9-ethoxy-1,2,3,4,4a,10b-hexahydro-8-methoxy-2-methylbenzo[c][1,6]naphthyridin-6-yl]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 667464-18-8 CAPLUS

CN Benzamide, 4-[(4aR,10bS)-9-ethoxy-1,2,3,4,4a,10b-hexahydro-8-methoxy-2-methylbenzo[c][1,6]naphthyridin-6-yl]-N-[imino[(1R)-1-phenylethyl]amino]methyl]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 667464-19-9 CAPLUS

CN Benzamide, 4-[(4aR,10bS)-9-ethoxy-1,2,3,4,4a,10b-hexahydro-8-methoxy-2-methylbenzo[c][1,6]naphthyridin-6-yl]-N-[imino[(1S)-1-phenylethyl]amino]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 667464-20-2 CAPLUS

CN Benzamide, 4-[(4aR,10bS)-9-ethoxy-1,2,3,4,4a,10b-hexahydro-8-methoxy-2-methylbenzo[c][1,6]naphthyridin-6-yl]-N-[imino[4-(phenylmethyl)-1-piperazinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 667464-21-3 CAPLUS

CN Benzamide, 4-[(4aR,10bS)-9-ethoxy-1,2,3,4,4a,10b-hexahydro-8-methoxy-2-methylbenzo[c][1,6]naphthyridin-6-yl]-N-[imino[4-(2-methoxyphenyl)-1-piperazinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 667464-22-4 CAPLUS

CN Benzamide, N-[(3,5-dimethyl-1H-pyrazol-1-yl)iminomethyl]-4-[(4aR,10bS)-9-ethoxy-1,2,3,4,4a,10b-hexahydro-8-methoxy-2-methylbenzo[c][1,6]naphthyridin-6-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 667464-24-6 CAPLUS

CN Benzamide, 4-[(4aR,10bS)-9-ethoxy-1,2,3,4,4a,10b-hexahydro-8-methoxy-2-methylbenzo[c][1,6]naphthyridin-6-yl]-N-[imino(1-naphthalenylamino)methyl]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 667464-25-7 CAPLUS

CN Benzamide, 4-[(4aR,10bS)-9-ethoxy-1,2,3,4,4a,10b-hexahydro-8-methoxy-2-methylbenzo[c][1,6]naphthyridin-6-yl]-N-[imino[(4-methyl-2-thiazolyl)amino]methyl]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 667464-26-8 CAPLUS

CN Benzamide, N-[(3,4-dihydro-2(1H)-isoquinolinyl)iminomethyl]-4-[(4aR,10bS)-9-ethoxy-1,2,3,4,4a,10b-hexahydro-8-methoxy-2-methylbenzo[c][1,6]naphthyridin-6-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 667464-27-9 CAPLUS

CN Benzamide, N-[(1H-benzimidazol-2-ylamino)iminomethyl]-4-[(4aR,10bS)-9-ethoxy-1,2,3,4,4a,10b-hexahydro-8-methoxy-2-methylbenzo[c][1,6]naphthyridin-6-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 667464-28-0 CAPLUS

CN Benzamide, 4-[(4aR,10bS)-9-ethoxy-1,2,3,4,4a,10b-hexahydro-8-methoxy-2-methylbenzo[c][1,6]naphthyridin-6-yl]-N-[imino(phenylamino)methyl] - (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 667464-29-1 CAPLUS

CN Benzamide, 4-[(4aR,10bS)-9-ethoxy-1,2,3,4,4a,10b-hexahydro-8-methoxy-2-methylbenzo[c][1,6]naphthyridin-6-yl]-N-(imino-4-thiomorpholinylmethyl) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 667464-30-4 CAPLUS

CN Benzamide, 4-[(4aR,10bS)-9-ethoxy-1,2,3,4,4a,10b-hexahydro-8-methoxy-2-methylbenzo[c][1,6]naphthyridin-6-yl]-N-[imino[4-[3-(trifluoromethyl)phenyl]-1-piperazinyl]methyl]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 667464-31-5 CAPLUS

CN Benzamide, 4-[(4aR,10bS)-9-ethoxy-1,2,3,4,4a,10b-hexahydro-8-methoxy-2-methylbenzo[c][1,6]naphthyridin-6-yl]-N-[imino(4-phenyl-1-piperazinyl)methyl]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 667464-32-6 CAPLUS

CN Benzamide, N-[(cyanoamino)iminomethyl]-4-[(4aR,10bS)-9-ethoxy-1,2,3,4,4a,10b-hexahydro-8-methoxy-2-methylbenzo[c][1,6]naphthyridin-6-yl]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 667464-33-7 CAPLUS

CN Benzamide, 4-[(4aR,10bS)-9-ethoxy-1,2,3,4,4a,10b-hexahydro-8-methoxy-2-methylbenzo[c][1,6]naphthyridin-6-yl]-N-[imino[2-(4-morpholinyl)ethyl]amino]methyl]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 667464-34-8 CAPLUS

CN Benzamide, N-[[[2-(3,4-dimethoxyphenyl)ethyl]amino]iminomethyl]-4-
 [(4aR,10bS)-9-ethoxy-1,2,3,4,4a,10b-hexahydro-8-methoxy-2-
 methylbenzo[c][1,6]naphthyridin-6-yl] - (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A

|
OMe

RN 667464-35-9 CAPLUS

CN Benzamide, N-[[[(3,4-dimethoxyphenyl)methyl]amino]iminomethyl]-4-
[(4aR,10bS)-9-ethoxy-1,2,3,4,4a,10b-hexahydro-8-methoxy-2-
methylbenzo[c][1,6]naphthyridin-6-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry..



RN 667464-36-0 CAPLUS

CN Benzamide, 4-[(4aR,10bS)-9-ethoxy-1,2,3,4,4a,10b-hexahydro-8-methoxy-2-
methylbenzo[c][1,6]naphthyridin-6-yl]-N-[imino[4-(phenylmethyl)-1-
piperidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 667464-37-1 CAPLUS

CN Benzamide, N-[(3,4-dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)iminomethyl]-
4-[(4aR,10bS)-9-ethoxy-1,2,3,4,4a,10b-hexahydro-8-methoxy-2-
methylbenzo[c][1,6]naphthyridin-6-yl]- (9CI) (CA INDEX NAME)

10459457


Absolute stereochemistry.



RN 667464-38-2 CAPLUS

CN Benzamide, N-[[bis(2-methoxyethyl)amino]iminomethyl]-4-[(4aR,10bS)-9-ethoxy-1,2,3,4,4a,10b-hexahydro-8-methoxy-2-methylbenzo[c][1,6]naphthyridin-6-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 667464-39-3 CAPLUS

CN Benzamide, 4-[(4aR,10bS)-9-ethoxy-1,2,3,4,4a,10b-hexahydro-8-methoxy-2-methylbenzo[c][1,6]naphthyridin-6-yl]-N-[[4-[2-(2-hydroxyethoxy)ethyl]-1-piperazinyl]iminomethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 667464-40-6 CAPLUS

CN Benzamide, N-[[4-(1,3-benzodioxol-5-ylmethyl)-1-piperazinyl]iminomethyl]-4-[(4aR,10bS)-9-ethoxy-1,2,3,4,4a,10b-hexahydro-8-methoxy-2-methylbenzo[c][1,6]naphthyridin-6-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 667464-41-7 CAPLUS

CN Benzamide, N-[(4-cyclohexyl-1-piperazinyl)iminomethyl]-4-[(4aR,10bS)-9-ethoxy-1,2,3,4,4a,10b-hexahydro-8-methoxy-2-methylbenzo[c][1,6]naphthyridin-6-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN . 667464-42-8 CAPLUS

CN 1-Piperazineacetic acid, 4-[[[4-[(4aR,10bS)-9-ethoxy-1,2,3,4,4a,10b-hexahydro-8-methoxy-2-methylbenzo[c][1,6]naphthyridin-6-yl]benzoyl]amino]iminomethyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 667464-43-9 CAPLUS

CN Benzamide, N-[[4-(4-acetylphenyl)-1-piperazinyl]iminomethyl]-4-[(4aR,10bS)-9-ethoxy-1,2,3,4,4a,10b-hexahydro-8-methoxy-2-methylbenzo[c][1,6]naphthyridin-6-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [R1 = alkyl; R2 and R3 independently = OH, alkoxy, cycloalkoxy, cycloalkylmethoxy or fluorinated alkoxy; or R2 and R3 together are a 1-2C alkylenedioxy; R4 = H, halo, NO₂, alkyl, CF₃ or alkoxy; and R5 = (un)substituted guanidino radical], are novel effective PDE3/4 inhibitors. Thus, II was prepared by reaction of 4-(cis-9-ethoxy-8-methoxy-2-methyl-1,2,3,4,4a,10b-hexahydrobenzo[c][1,6]naphthyridin-6-yl)benzoyl chloride with N-amidinomorpholine in acetonitrile in the presence of triethylamine. I possessed -log IC₅₀ values (mol/L) of 7.71-9.65 in inhibition of PDE4 and 6.05-7.37 for PDE3. As phosphodiesterase inhibitors, I are useful as medicaments for treating respiratory disorders and/or dermatosis.

AN 2002:658122 CAPLUS

DN 137:185479

TI Preparation of Phenylbenzonaphthyridines as Phosphodiesterase Inhibitors (PDE3/4)

IN Gutterer, Beate; Grundler, Gerhard; Hatzelmann, Armin; Beume, Rolf; Bundschuh, Daniela; Kley, Hans-Peter; Nave, Ruediger; Zech, Karl; Reutter, Felix; Flockerzi, Dieter

PA BYK Gulden Lomberg Chemische Fabrik G.m.b.H., Germany; Atlanta Pharma. AG

SO PCT Int. Appl., 43 pp.

CODEN: PIXXD2

DT Patent


LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002066476	A1	20020829	WO 2002-EP1819	20020221
	WO 2002066476	A9	20031030		
W:	AE, AL, AU, BA, BG, BR, CA, CN, CO, CU, CZ, DZ, EC, EE, GE, HR, HU, ID, IL, IN, IS, JP, KR, LT, LV, MA, MK, MX, NO, NZ, PH, PL, RO, SG, SI, SK, TN, UA, US, VN, YU, ZA, ZW				
RW:	AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				

CA 2438717	A1	20020829	CA 2002-2438717	20020221
AU 2002253045	A1	20020904	AU 2002-253045	20020221
AU 2002253045	B2	20070712		
EP 1377574	A1	20040107	EP 2002-722110	20020221
EP 1377574	B1	20050119		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004526712	T	20040902	JP 2002-565990	20020221
AT 287403	T	20050215	AT 2002-722110	20020221
PT 1377574	T	20050531	PT 2002-722110	20020221
ES 2236504	T3	20050716	ES 2002-2722110	20020221
US 2004097537	A1	20040520	US 2003-467568	20030808
US 6936622	B2	20050830		
PRAI EP 2001-104086	A	20010221		
WO 2002-EP1819	W	20020221		
OS MARPAT 137:185479				
IT 451486-62-7P				
451486-63-8P				
451486-64-9P				
451486-65-0P				
451486-66-1P				
451486-67-2P				
451486-68-3P				
451486-69-4P				
451486-70-7P				
451486-71-8P				
451486-72-9P				
451486-73-0P				
451486-74-1P				
451486-76-3P				
451486-78-5P				
451486-79-6P				
451486-80-9P				
451486-81-0P				
451486-82-1P				
451486-83-2P				
451486-84-3P				
451486-85-4P				
451486-86-5P				
451486-87-6P				
451486-88-7P				
451486-89-8P				
451486-90-1P				
451486-91-2P				
451486-92-3P				
451486-93-4P				
451486-94-5P				
451486-97-8P				
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
(target compound; preparation of phosphodiesterase inhibitors phenylbenzonaphthyridines as medicaments for respiratory disorders)				
RN 451486-62-7	CAPLUS			
CN	Benzamide, 4-[(4aR,10bS)-9-ethoxy-1,2,3,4,4a,10b-hexahydro-8-methoxy-2-methylbenzo[c][1,6]naphthyridin-6-yl]-N-(imino-4-morpholinylmethyl)-, dihydrochloride, rel-(+)- (9CI) (CA INDEX NAME)			

Rotation (+). Absolute stereochemistry unknown.




● 2 HCl

RN 451486-63-8 CAPLUS

CN Benzamide, 4-[(4aR,10bS)-9-ethoxy-1,2,3,4,4a,10b-hexahydro-8-methoxy-2-methylbenzo[c][1,6]naphthyridin-6-yl]-N-(imino-4-morpholinylmethyl)-, rel-(+)- (9CI) (CA INDEX NAME)


Rotation (+). Absolute stereochemistry unknown.



RN 451486-64-9 CAPLUS

CN Benzamide, N-[(diethylamino)iminomethyl]-4-[(4aR,10bS)-9-ethoxy-1,2,3,4,4a,10b-hexahydro-8-methoxy-2-methylbenzo[c][1,6]naphthyridin-6-yl]-, dihydrochloride, rel-(+)- (9CI) (CA INDEX NAME)

Rotation (+). Absolute stereochemistry unknown.




● 2 HCl

RN 451486-65-0 CAPLUS

CN Benzamide, N-[(diethylamino)iminomethyl]-4-[(4aR,10bS)-9-ethoxy-1,2,3,4,4a,10b-hexahydro-8-methoxy-2-methylbenzo[c][1,6]naphthyridin-6-yl]-, rel-(+)- (9CI) (CA INDEX NAME)


Rotation (+). Absolute stereochemistry unknown.



RN 451486-66-1 CAPLUS

CN Benzamide, N-[(dimethylamino)iminomethyl]-4-[(4aR,10bS)-9-ethoxy-1,2,3,4,4a,10b-hexahydro-8-methoxy-2-methylbenzo[c][1,6]naphthyridin-6-yl]-, dihydrochloride, rel-(+)- (9CI) (CA INDEX NAME)

Rotation (+). Absolute stereochemistry unknown.




●2: HCl

RN 451486-67-2 CAPLUS

CN Benzamide, N-[(dimethylamino)iminomethyl]-4-[(4aR,10bS)-9-ethoxy-1,2,3,4,4a,10b-hexahydro-8-methoxy-2-methylbenzo[c][1,6]naphthyridin-6-yl]-, rel-(+)- (9CI) (CA INDEX NAME)


Rotation (+). Absolute stereochemistry unknown.



RN 451486-68-3 CAPLUS

CN Benzamide, 4-[(4aR,10bS)-9-ethoxy-1,2,3,4,4a,10b-hexahydro-8-methoxy-2-methylbenzo[c][1,6]naphthyridin-6-yl]-N-[[2-hydroxyethyl)methylamino]iminomethyl]-, dihydrochloride, rel-(+)- (9CI) (CA INDEX NAME)

Rotation (+). Absolute stereochemistry unknown.




● 2 HCl

RN 451486-69-4 CAPLUS

CN Benzamide, 4-[(4aR,10bS)-9-ethoxy-1,2,3,4,4a,10b-hexahydro-8-methoxy-2-methylbenzo[c][1,6]naphthyridin-6-yl]-N-[[2-hydroxyethyl)methylamino]iminomethyl]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 451486-70-7 CAPLUS

CN Benzamide, N-[bis(dimethylamino)methylene]-4-[(4aR,10bS)-9-ethoxy-1,2,3,4,4a,10b-hexahydro-8-methoxy-2-methylbenzo[c][1,6]naphthyridin-6-yl]-, monohydrochloride, rel-(-)- (9CI) (CA INDEX NAME)

Rotation (-). Absolute stereochemistry unknown.




● HCl

RN 451486-71-8 CAPLUS

CN Benzamide, N-[bis(dimethylamino)methylene]-4-[(4aR,10bS)-9-ethoxy-1,2,3,4,4a,10b-hexahydro-8-methoxy-2-methylbenzo[c][1,6]naphthyridin-6-yl]-, rel-(-)- (9CI) (CA INDEX NAME)


Rotation (-). Absolute stereochemistry unknown.



RN 451486-72-9 CAPLUS

CN Benzamide, 4-[(4aR,10bS)-9-ethoxy-1,2,3,4,4a,10b-hexahydro-8-methoxy-2-methylbenzo[c][1,6]naphthyridin-6-yl]-N-[imino(4-methyl-1-piperazinyl)methyl]-, dihydrochloride, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● 2 HCl

RN 451486-73-0 CAPLUS

CN Benzamide, 4-[(4aR,10bS)-9-ethoxy-1,2,3,4,4a,10b-hexahydro-8-methoxy-2-methylbenzo[c][1,6]naphthyridin-6-yl]-N-[imino(4-methyl-1-piperazinyl)methyl]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 451486-74-1 CAPLUS

CN Benzamide, N-(aminoiminomethyl)-4-[(4aR,10bS)-9-ethoxy-1,2,3,4,4a,10b-hexahydro-8-methoxy-2-methylbenzo[c][1,6]naphthyridin-6-yl]-, rel-(-)-(9CI) (CA INDEX NAME)


Rotation (-). Absolute stereochemistry unknown.



RN 451486-76-3 CAPLUS

CN Benzamide, N-[(dimethylamino)iminomethyl]-4-[(4aR,10bS)-1,2,3,4,4a,10b-hexahydro-8,9-dimethoxy-2-methylbenzo[c][1,6]naphthyridin-6-yl]-, monohydrochloride, rel-(-)-(9CI) (CA INDEX NAME)

Rotation (-). Absolute stereochemistry unknown.




● HCl

RN 451486-78-5 CAPLUS

CN Benzamide, N-[(dimethylamino)iminomethyl]-4-[(4aR,10bS)-1,2,3,4,4a,10b-hexahydro-8,9-dimethoxy-2-methylbenzo[c][1,6]naphthyridin-6-yl]-, rel-(-)-(9CI) (CA INDEX NAME)


Rotation (-). Absolute stereochemistry unknown.



RN 451486-79-6 CAPLUS

CN Benzamide, N-[bis(dimethylamino)methylene]-4-[(4aR,10bS)-1,2,3,4,4a,10b-hexahydro-8,9-dimethoxy-2-methylbenzo[c][1,6]naphthyridin-6-yl]-, monohydrochloride, rel-(-)-(9CI) (CA INDEX NAME)

Rotation (-). Absolute stereochemistry unknown.




● HCl

RN 451486-80-9 CAPLUS

CN Benzamide, N-[bis(dimethylamino)methylene]-4-[(4aR,10bS)-1,2,3,4,4a,10b-hexahydro-8,9-dimethoxy-2-methylbenzo[c][1,6]naphthyridin-6-yl]-, rel-(-)-(9CI) (CA INDEX NAME)


Rotation (-). Absolute stereochemistry unknown.



RN 451486-81-0 CAPLUS

CN Benzamide, N-[(dimethylamino)iminomethyl]-3-[(4aR,10bS)-9-ethoxy-1,2,3,4,4a,10b-hexahydro-8-methoxy-2-methylbenzo[c][1,6]naphthyridin-6-yl]-, rel-(-)(9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 451486-82-1 CAPLUS

CN Benzamide, 4-[(4aR,10bS)-9-ethoxy-1,2,3,4,4a,10b-hexahydro-8-methoxy-2-methylbenzo[c][1,6]naphthyridin-6-yl]-N-(imino-1-pyrrolidinylmethyl)-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 451486-83-2 CAPLUS

CN Benzamide, N-(aminoiminomethyl)-4-[(4aR,10bS)-1,2,3,4,4a,10b-hexahydro-8,9-dimethoxy-2-methylbenzo[c][1,6]naphthyridin-6-yl]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 451486-84-3 CAPLUS

CN Benzamide, N-[(dimethylamino)(methylamino)methylene]-4-[(4aR,10bS)-9-ethoxy-1,2,3,4,4a,10b-hexahydro-8-methoxy-2-methylbenzo[c][1,6]naphthyridin-6-yl]-, monohydrochloride, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 451486-85-4 CAPLUS

CN Benzamide, N-[(dimethylamino)(methylamino)methylene]-4-[(4aR,10bS)-9-ethoxy-1,2,3,4,4a,10b-hexahydro-8-methoxy-2-methylbenzo[c][1,6]naphthyridin-6-yl]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 451486-86-5 CAPLUS

CN Benzamide, 4-[(4aR,10bS)-9-ethoxy-1,2,3,4,4a,10b-hexahydro-8-methoxy-2-methylbenzo[c][1,6]naphthyridin-6-yl]-N-[imino(methylamino)methyl]-, rel-(-)-(9CI) (CA INDEX NAME)


Rotation (-). Absolute stereochemistry unknown.



RN 451486-87-6 CAPLUS

CN Benzamide, 4-[(4aR,10bS)-9-ethoxy-1,2,3,4,4a,10b-hexahydro-8-methoxy-2-methylbenzo[c][1,6]naphthyridin-6-yl]-N-[imino[(1-methylethyl)amino]methyl]-, rel-(-)-(9CI) (CA INDEX NAME)


Rotation (-). Absolute stereochemistry unknown.



RN 451486-88-7 CAPLUS

CN Benzamide, 4-[(4aR,10bS)-9-ethoxy-1,2,3,4,4a,10b-hexahydro-8-methoxy-2-methylbenzo[c][1,6]naphthyridin-6-yl]-N-[imino(propylamino)methyl]-, rel-(-)- (9CI) (CA INDEX NAME)


Rotation (-). Absolute stereochemistry unknown.



RN 451486-89-8 CAPLUS

CN Benzamide, 4-[(4aR,10bS)-9-ethoxy-1,2,3,4,4a,10b-hexahydro-8-methoxy-2-methylbenzo[c][1,6]naphthyridin-6-yl]-N-[imino[(2-methylpropyl)amino]methyl]-, rel-(-)- (9CI) (CA INDEX NAME)


Rotation (-). Absolute stereochemistry unknown.



RN 451486-90-1 CAPLUS

CN Benzamide, 4-[(4aR,10bS)-9-ethoxy-1,2,3,4,4a,10b-hexahydro-8-methoxy-2-methylbenzo[c][1,6]naphthyridin-6-yl]-N-[(ethylamino)iminomethyl]-, rel-(-)-(9CI) (CA INDEX NAME)


Rotation (-). Absolute stereochemistry unknown.



RN 451486-91-2 CAPLUS

CN Benzamide, N-[(cyclohexylamino)iminomethyl]-4-[(4aR,10bS)-9-ethoxy-1,2,3,4,4a,10b-hexahydro-8-methoxy-2-methylbenzo[c][1,6]naphthyridin-6-yl]-, rel-(-)-(9CI) (CA INDEX NAME)


Rotation (-). Absolute stereochemistry unknown.



RN 451486-92-3 CAPLUS

CN Benzamide, N-[[[(cyclohexylmethyl)amino]iminomethyl]-4-[(4aR,10bS)-9-ethoxy-1,2,3,4,4a,10b-hexahydro-8-methoxy-2-methylbenzo[c][1,6]naphthyridin-6-yl]-, rel-(-)-(9CI) (CA INDEX NAME)


Rotation (-). Absolute stereochemistry unknown.



RN 451486-93-4 CAPLUS

CN Benzamide, N-[(butylamino)iminomethyl]-4-[(4aR,10bS)-9-ethoxy-1,2,3,4,4a,10b-hexahydro-8-methoxy-2-methylbenzo[c][1,6]naphthyridin-6-yl]-, rel-(-)-(9CI) (CA INDEX NAME)


Rotation (-). Absolute stereochemistry unknown.



RN 451486-94-5 CAPLUS

CN Benzamide, N-[(dimethylamino)iminomethyl]-4-[(4aR,10bS)-9-ethoxy-1,2,3,4,4a,10b-hexahydro-8-methoxy-2-methyl-2-oxidobenzo[c][1,6]naphthyridin-6-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 451486-97-8 CAPLUS


CN Benzamide, N-[(dimethylamino)iminomethyl]-4-[(4aR,10bS)-9-ethoxy-1,2,3,4,4a,10b-hexahydro-8-methoxy-2-methylbenzo[c][1,6]naphthyridin-6-yl]-, rel-(+)-, (2R,3R)-2,3-dihydroxybutanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 451486-67-2

CMF C26 H33 N5 O3


Rotation (+). Absolute stereochemistry unknown.



CM 2

CRN 87-69-4
CMF C4 H6 O6

Absolute stereochemistry.



RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d l2 fbib 1-2

YOU HAVE REQUESTED DATA FROM FILE 'REGISTRY' - CONTINUE? (Y)/N:n

=> d his

(FILE 'HOME' ENTERED AT 17:32:42 ON 25 SEP 2007)

FILE 'REGISTRY' ENTERED AT 17:32:54 ON 25 SEP 2007

L1 STRUCTURE UPLOADED

L2 5 S L1

L3 61 S L1 FUL

FILE 'CAPLUS' ENTERED AT 17:33:22 ON 25 SEP 2007

L4 2 S L3

=> d l4 1-2 fbib

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2004:182877 CAPLUS

DN 140:235693

TI Preparation of benzonaphthyridines as phosphodiesterase PDE4 or PDE3/4

10459457

inhibitors.

IN Kautz, Ulrich; Schmidt, Beate; Weinbrenner, Steffen; Hatzelmann, Armin;
Barsig, Johannes; Marx, Degenhard; Kley, Hans-Peter; David, Michael;
Rocker, Dirk; Flockerzi, Dieter

PA Altana Pharma A.-G., Germany

SO PCT Int. Appl., 65 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004018465	A2	20040304	WO 2003-EP8996	20030813
	WO 2004018465	A3	20040527		
	WO 2004018465	A9	20050915		
	W:	AE, AL, AU, BA, BR, CA, CN, CO, DZ, EC, GE, HR, ID, IL, IN, IS, JP, KR, LT, LV, MA, MK, MX, NO, NZ, PH, PL, SG, TN, UA, US, VN, YU, ZA, ZW			
	RW:	AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR			
	CA 2495603	A1	20040304	EP 2002-18529	A 20020817
				CA 2003-2495603	20030813
				EP 2002-18529	A 20020817
				WO 2003-EP8996	W 20030813
	AU 2003263216	A1	20040311	AU 2003-263216	20030813
				EP 2002-18529	A 20020817
				WO 2003-EP8996	W 20030813
	EP 1581533	A2	20051005	EP 2003-792314	20030813
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
				EP 2002-18529	A 20020817
				WO 2003-EP8996	W 20030813
	JP 2005537313	T	20051208	JP 2004-530142	20030813
				EP 2002-18529	A 20020817
				WO 2003-EP8996	W 20030813

OS MARPAT 140:235693

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2002:658122 CAPLUS

DN 137:185479

TI Preparation of Phenylbenzonaphthyridines as Phosphodiesterase Inhibitors (PDE3/4)

IN Gutterer, Beate; Grundler, Gerhard; Hatzelmann, Armin; Beume, Rolf; Bundschuh, Daniela; Kley, Hans-Peter; Nave, Ruediger; Zech, Karl; Reutter, Felix; Flockerzi, Dieter

PA BYK Gulden Lomberg Chemische Fabrik G.m.b.H., Germany; Atlanta Pharma. AG

SO PCT Int. Appl., 43 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002066476	A1	20020829	WO 2002-EP1819	20020221
	WO 2002066476	A9	20031030		
	W:	AE, AL, AU, BA, BG, BR, CA, CN, CO, CU, CZ, DZ, EC, EE, GE, HR, HU, ID, IL, IN, IS, JP, KR, LT, LV, MA, MK, MX, NO, NZ, PH, PL, RO, SG, SI, SK, TN, UA, US, VN, YU, ZA, ZW			

RW: AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR

CA 2438717	A1	20020829	EP 2001-104086	A	20010221
			CA 2002-2438717		20020221
			EP 2001-104086	A	20010221
AU 2002253045	A1	20020904	WO 2002-EP1819	W	20020221
AU 2002253045	B2	20070712	AU 2002-253045		20020221
			EP 2001-104086	A	20010221
			WO 2002-EP1819	W	20020221
EP 1377574	A1	20040107	EP 2002-722110		20020221
EP 1377574	B1	20050119			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
			EP 2001-104086	A	20010221
			WO 2002-EP1819	W	20020221
JP 2004526712	T	20040902	JP 2002-565990		20020221
			EP 2001-104086	A	20010221
			WO 2002-EP1819	W	20020221
AT 287403	T	20050215	AT 2002-722110		20020221
			EP 2001-104086	A	20010221
			WO 2002-EP1819	W	20020221
PT 1377574	T	20050531	PT 2002-722110		20020221
			EP 2001-104086	A	20010221
			WO 2002-EP1819	W	20020221
ES 2236504	T3	20050716	ES 2002-2722110		20020221
			EP 2001-104086	A	20010221
US 2004097537	A1	20040520	US 2003-467568		20030808
US 6936622	B2	20050830			
			EP 2001-104086	A	20010221
			WO 2002-EP1819	W	20020221

OS MARPAT 137:185479

RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> s US 20060113968/pn
L5 0 US 20060113968/PN
(US2006113968/PN)

=> s US20060113968/pn
L6 0 US20060113968/PN
(US2006113968/PN)

=> s US2006-0113968/pn
L7 0 US2006-0113968/PN
(US2006113968/PN)

=> file stnguide
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
25.51	197.82

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
-1.56	-1.56

CA SUBSCRIBER PRICE

FILE 'STNGUIDE' ENTERED AT 17:41:46 ON 25 SEP 2007
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT

26/09/2007

Page 39

COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.

LAST RELOADED: Sep 24, 2007 (20070924/UP).

10459457